单克隆抗体抗肿瘤药作为一种独具优势的生物靶向药物，因其特异性强、耐受性好等特点，在肿瘤治疗中占有越来越重要的地位，然而我国的单克隆抗体抗肿瘤药物的发展依然具有很高的技术门槛，用药主要依靠进口。对2011-2017年FDA批准的单克隆抗体抗肿瘤药物进行总结，按照作用靶点及其临床适应症等进行综述，以供我国医药相关人员参考。

Monoclonal antibody anti-tumor drug, used as an unique biological target drug, occupies an increasingly important position in tumor treatment because of the strong specificity and good tolerance. However, the development of monoclonal antibody anti-tumor drug in China still faces high technical threshold, and the drug use mainly depends on imports. The anti-tumor drugs of monoclonal antibody approved by FDA from 2011 to 2017 are summarized according to the action target and clinical indication in this paper, and in order to provide references for medical personnel in China.